Cadila forms JV with Novavax to develop vaccines in India
Indian pharma company Cadila Pharmaceuticals and Novavax (vaccines for infectious diseases) have formed CPL Biologicals Ltd., a joint venture to develop and market Novavax's seasonal influenza virus-like-particle-based (VLP) vaccine drug candidate and Cadila's cancer vaccines, adjuvants, biogeneric products, and diagnostics in India.
- Drug Delivery
- Specialty Pharmaceuticals
- Includes Equity
- Joint Venture
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.